Related Experiment Videos
Preclinical assessment of the antibacterial activity of nebramycin factor 6
Antimicrobial Agents and Chemotherapy
|January 1, 1970
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2001
Oral antimicrobial susceptibilities of Streptococcus pyogenes recently isolated in five countries.
International journal of clinical practice·2001
Assessment of the susceptibility of Streptococcus pneumoniae to cefaclor and loracarbef in 13 countries.
Journal of chemotherapy (Florence, Italy)·2000
In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
Antimicrobial agents and chemotherapy·2000
Cefaclor: a contemporary look at susceptibility of key pathogens from around the globe.
Journal of chemotherapy (Florence, Italy)·1998
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Antimicrobial agents and chemotherapy·1996
In vitro activity of zosurabalpin against a global set of carbapenem-resistant-A. baumannii clinical isolates.
Antimicrobial agents and chemotherapy·2026
N-terminal lysine as a critical determinant of odilorhabdin susceptibility to inactivation by the self-resistance acetyltransferase OatA.
Antimicrobial agents and chemotherapy·2026
Amphotericin B resistance in Lomentospora prolificans is associated with a soluble cell wall component.
Antimicrobial agents and chemotherapy·2026
Mechanistic blockade of RSV infection by a pre-F targeting single-domain antibody-Fc fusion protein.
Antimicrobial agents and chemotherapy·2026
In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution.
Antimicrobial agents and chemotherapy·2026